225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks
Affiliations
Affiliations
- Jaber Al-Ahmad Centre for Nuclear Medicine and Molecular Imaging, Kuwait City, Kuwait.
- Government College University, Faisalabad, Pakistan.
Abstract
Ac-based PSMA-targeted therapy has emerged as promising agent for the treatment of metastatic castration-resistant prostate cancer. Posttherapy image is used for tracer localization and dosimetry. Prior 2 photopeaks of 440 and 218 KeV were reported for posttherapy imaging. Our study of gamma ray spectrum, phantom, and clinical images show that imaging with 3 major photopeaks of 78, 218, and 440 KeV gives better quality images, high count statistics, and higher number of lesion delineations. It is therefore suggested that posttherapy imaging may be carried out using 3 major abundant photopeaks.
Similar articles
Vatsa R, Sood A, Vadi SK, Das CK, Kaur K, Parmar M, Mittal BR.Clin Nucl Med. 2020 Jun;45(6):437-438. doi: 10.1097/RLU.0000000000003031.PMID: 32366786
Okamoto S, Thieme A, Allmann J, D'Alessandria C, Maurer T, Retz M, Tauber R, Heck MM, Wester HJ, Tamaki N, Fendler WP, Herrmann K, Pfob CH, Scheidhauer K, Schwaiger M, Ziegler S, Eiber M.J Nucl Med. 2017 Mar;58(3):445-450. doi: 10.2967/jnumed.116.178483. Epub 2016 Sep 22.PMID: 27660138
Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A.J Nucl Med. 2018 May;59(5):795-802. doi: 10.2967/jnumed.117.203539. Epub 2018 Jan 11.PMID: 29326358
[PSMA-targeted radioligand therapy in prostate cancer].
Heck MM, Retz M, Tauber R, Knorr K, Kratochwil C, Eiber M.Urologe A. 2017 Jan;56(1):32-39. doi: 10.1007/s00120-016-0274-3.PMID: 27885457 Review. German.
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. doi: 10.2967/jnumed.115.170720.PMID: 27694178 Review.
Cited by
Delker A, Schleske M, Liubchenko G, Berg I, Zacherl MJ, Brendel M, Gildehaus FJ, Rumiantcev M, Resch S, Hürkamp K, Wenter V, Unterrainer LM, Bartenstein P, Ziegler SI, Beyer L, Böning G.Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.PMID: 36629878 Free PMC article.
Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares RM, Abergel RJ.Front Med (Lausanne). 2022 Dec 22;9:1020188. doi: 10.3389/fmed.2022.1020188. eCollection 2022.PMID: 36619636 Free PMC article. Review.
Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J.Front Med (Lausanne). 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. eCollection 2022.PMID: 36569154 Free PMC article. Review.
Caravaca J, Huh Y, Gullberg GT, Seo Y.IEEE Trans Radiat Plasma Med Sci. 2022 Nov;6(8):904-915. doi: 10.1109/trpms.2022.3166116. Epub 2022 Apr 11.PMID: 36338821
Radionuclides for Targeted Therapy: Physical Properties.
Stokke C, Kvassheim M, Blakkisrud J.Molecules. 2022 Aug 25;27(17):5429. doi: 10.3390/molecules27175429.PMID: 36080198 Free PMC article. Review.